Global Point of Care or HIV Self-Test Market

Global Point of Care or HIV Self-Test Market Size, Trends & Analysis - Forecasts to 2026 By Sample Type (Urine Sample & Blood Sample), By Technology (Second Generation Self-Test, Third Generation Self-Test, and Fourth Generation Self-Test), By Product Type (Self Sampling and Self-Testing), By End-User (Home Healthcare, Hospitals & Clinics, E-Commerce Channels and Diagnostic Laboratories), Competitive Landscape Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on April 18 2024 with the latest and most recent market numbers

Point of Care/ HIV Self-Test Market Insights

Human Immunodeficiency Virus or most popularly called HIV is a virus that attacks healthy cells of the body which are responsible to maintain the immune system. They attack those specific cells that help the human body fight infection, diseases, and complications. With this, the HIV or the Human Immunodeficiency Virus makes the human body extremely sensitive to infection and highly vulnerable to other deadly diseases. The spread of this virus is not airborne or waterborne but it is spread with close sexual contact and bodily fluids. HIV infects those people who are constantly in the process of having unprotected intercourse or through sharing injections/ syringes with the infected person. Untreated HIV leads to the disease called AIDS (acquired immunodeficiency syndrome). This disease is considered to be the last stage of the infection caused by HIV. A person with AIDS loses its immunity and becomes easily susceptible to any kind of infection or disease. As per WHO statistics, as of 2019, the US is home to more than 1.2 million (children and adults) HIV AIDS patients. Also, as per CDC latest information, ~ 14% (or 1 in 7) of young people in the US have been living with HIV and have been recommended to keep testing themselves. Moreover, this virus has affected more than 2.5 million people in India making this country the 3rd largest country with the highest number of HIV cases. Hence, with the high incidence of HIV cases, there is a need to conduct HIV screening and tests to track and treat the ill effects of HIV and AIDS. Therefore, the market of diagnostics has been seeing an increasing trend of using home-based or at-home, or self-test HIV kits to rule out the possible HIV infection cases at point-of-care level. Many manufacturers have taken a keen interest in launching their home-based HIV self-test kit in major markets such as the US, UK, Australia, India, China, Japan and other countries. Moreover, this market will foresee a rise in its revenue size owing to a major driver i.e. increasing research and development initiatives to launch fourth-generation technology-based test kits which offer to test IgG and IgM both simultaneously. With the rising cases of pediatric HIV infections, the market is ought to be growing rapidly especially for hospitals and clinics who are the major end-users. Also, with the rising cases of blood transfusion (as each donated blood bag requires to undergo specific tests including for HIV), and rising government initiatives for the awareness in developed countries will help the market grow exponentially.

However, due to lack of awareness regarding the importance of HIV screening and symptoms of AIDS, and the high cost of point of care testing kits, this market may face challenges to grow rapidly especially in low-income countries and developing countries. Moreover, this market will pick up its pace of growth only after most of the kits in the market get FDA approval and permission to launch in developed regions like North America and Europe. As most of the kits are not FDA approved, the market is ought to face a restraint in terms of its revenue generation.

global point of care or hiv self-test market

Point of Care/ HIV Self-Test Market: By Sample Type

Based on the sample type for the HIV self-testing analysis, the market can be classified into blood based or urine based sample. However owing to the higher number of products that are blood based and owing to the fact that 2nd and 3rd generation technology is fit for blood based test, the market for blood based segment will be the largest and also growing the fastest during the forecast period of 2021-2026.

Point of Care/ HIV Self-Test Market: By Product Type

The point of care/ HIV self-test market by product type can be segmented into self-sampling and self-testing products. Because of the added advantage of point of care testing, quick turnaround time for results, and user-friendly system of the product, the market for self-testing products will have the highest share in the market. However, owing to increased chances of accurate results using laboratory based methods, the market for self-sampling will be growing slightly faster than the latter one.

Point of Care/ HIV Self-Test Market: By Technology

Based on the innovative technology used to construct at-home HIV testing kits, the market can be segmented into second generation self-test, third generation self-test, and fourth generation self-test. The second generation self-test segment will be the largest segment owing to a higher number of products available in the market with this technology. Second generation technology includes the identification of IgG and not IgM for understanding the presence of HIV in the blood sample. However, 3rd generation technology which will be the fastest growing technology includes the screening of blood samples by identifying both IgG and IgM.

Point of Care/ HIV Self-Test Market: By End-User

Home healthcare, hospitals & clinics, e-commerce channels and diagnostic laboratories are the end-users identified for the point of care/ HIV self-test market. The home healthcare setting will be the largest shareholder in the market owing to the user-friendly design of the test which makes it comfortable to use by patients by themselves at home. The hospitals & clinics segment will have the highest CAGR value during the forecast period.

asia pacific point of care or hiv self-test market

Point of Care/ HIV Self-Test Market: By Region

As per the geographical analysis, the point of care/ HIV self-test market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central South America (Brazil, Argentina, and Rest of Central and South America). North America holds the highest position in the market in terms of sales revenue owing to major factors such as increasing awareness of HIV screening, rising incidence of AIDS in the US, presence of top market players and increasing number of product launch initiatives in the region. On the other side, the Asia Pacific will be growing the fastest solely because of the rapidly increasing cases of AIDS, an increasing number of blood transfusion cases, and the rising number of blood donors in the region.

Point of Care/ HIV Self-Test Market Share and Competitor Analysis

Atomo Diagnostics, Everlywell, autotest VIH, Biosure UK, Simplitude ByMe, Self Care Ltd., OraSure Technologies, Private iDNA, MyLAB Box, LetsGetChecked, Biosynex Group, bioLytical Laboratories Inc., Orange Life, Bedfordbiotech, Sedia Biosciences Corporation, and Chembio Diagnostic Systems are the players in the point of care/ HIV self-test market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Male Sexual Therapeutics Industry Overview, 2019-2026

2.1.1 Industry Overview

2.1.2 Product Overview

2.1.3 Therapeutic Type Overview

2.1.4 Distribution Channel Overview

2.1.6 Regional Overview

Chapter 3 Male Sexual Therapeutics Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2019-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Rising number of male geriatric population susceptible to sexual disorders

3.3.1.2 Rising Prevalence of male hypogonadism and prostate cancer

3.3.2 Industry Challenges

3.3.2.1 Lack of awareness regarding sexual wellbeing in male in developing nations

3.4 Prospective Growth Scenario

3.4.1 Product Growth Scenario

3.4.2 Therapeutic Type Growth Scenario

3.4.3 Distribution Channel Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Distribution Channel Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Male Sexual Therapeutics Market, By Product

4.1 Product Outlook

4.2 Capsules

4.2.1 Market Size, By Region, 2019-2026 (USD Million)

4.3 Hormone Injections

4.3.1 Market Size, By Region, 2019-2026 (USD Million)

4.4 Creams & Ointments

4.4.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 5 Male Sexual Therapeutics Market, By Therapeutic Type

5.1 Therapeutic Type Outlook

5.2 Male Hypogonadism Therapy

5.2.1 Market Size, By Region, 2019-2026 (USD Million)

5.3 Prostate Cancer Therapy

5.3.1 Market Size, By Region, 2019-2026 (USD Million)

5.4 Erectile Dysfunction Therapy

5.4.1 Market Size, By Region, 2019-2026 (USD Million)

5.5 Premature Ejaculation Therapy

5.5.1 Market Size, By Region, 2019-2026 (USD Million)

5.6 Others

5.6.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 6 Male Sexual Therapeutics Market, By Distribution Channel

6.1 Hospital Pharmacies

6.1.1 Market Size, By Region, 2019-2026 (USD Million)

6.2 Retail Pharmacies

6.2.1 Market Size, By Region, 2019-2026 (USD Million)

6.3 Online Pharmacies

6.3.1 Market Size, By Region, 2019-2026 (USD Million)

Chapter 8 Male Sexual Therapeutics Market, By Region

8.1 Regional outlook

8.2 North America

8.2.1 Market Size, By Country 2019-2026 (USD Million)

8.2.2 Market Size, By Product, 2019-2026 (USD Million)

8.2.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.2.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.2.6 U.S.

8.2.6.1 Market Size, By Product, 2019-2026 (USD Million)

8.2.4.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.2.4.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.2.7 Canada

8.2.7.1 Market Size, By Product, 2019-2026 (USD Million)

8.2.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.2.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3 Europe

8.3.1 Market Size, By Country 2019-2026 (USD Million)

8.3.2 Market Size, By Product, 2019-2026 (USD Million)

8.3.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3.6 Germany

8.3.6.1 Market Size, By Product, 2019-2026 (USD Million)

8.3.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3.7 UK

8.3.7.1 Market Size, By Product, 2019-2026 (USD Million)

8.3.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3.8 France

8.3.8.1 Market Size, By Product, 2019-2026 (USD Million)

8.3.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3.9 Italy

8.3.9.1 Market Size, By Product, 2019-2026 (USD Million)

8.3.9.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.9.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3.10 Spain

8.3.10.1 Market Size, By Product, 2019-2026 (USD Million)

8.3.10.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.10.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.3.11 Russia

8.3.11.1 Market Size, By Product, 2019-2026 (USD Million)

8.3.11.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.3.11.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.4 Asia Pacific

8.4.1 Market Size, By Country 2019-2026 (USD Million)

8.4.2 Market Size, By Product, 2019-2026 (USD Million)

8.4.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.4.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.4.6 China

8.4.6.1 Market Size, By Product, 2019-2026 (USD Million)

8.4.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.4.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.4.7 India

8.4.7.1 Market Size, By Product, 2019-2026 (USD Million)

8.4.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.4.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.4.8 Japan

8.4.8.1 Market Size, By Product, 2019-2026 (USD Million)

8.4.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.4.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.4.9 Australia

8.4.9.1 Market Size, By Product, 2019-2026 (USD Million)

8.4.9.2 Market size, By Therapeutic Type, 2019-2026 (USD Million)

8.4.9.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.4.10 South Korea

8.4.10.1 Market Size, By Product, 2019-2026 (USD Million)

8.4.10.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.4.10.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.5 Latin America

8.5.1 Market Size, By Country 2019-2026 (USD Million)

8.5.2 Market Size, By Product, 2019-2026 (USD Million)

8.5.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.5.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.5.6 Brazil

8.5.6.1 Market Size, By Product, 2019-2026 (USD Million)

8.5.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.5.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.5.7 Mexico

8.5.7.1 Market Size, By Product, 2019-2026 (USD Million)

8.5.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.5.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.5.8 Argentina

8.5.8.1 Market Size, By Product, 2019-2026 (USD Million)

8.5.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.5.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.6 MEA

8.6.1 Market Size, By Country 2019-2026 (USD Million)

8.6.2 Market Size, By Product, 2019-2026 (USD Million)

8.6.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.6.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.6.6 Saudi Arabia

8.6.6.1 Market Size, By Product, 2019-2026 (USD Million)

8.6.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.6.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.6.7 UAE

8.6.7.1 Market Size, By Product, 2019-2026 (USD Million)

8.6.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.6.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

8.6.8 South Africa

8.6.8.1 Market Size, By Product, 2019-2026 (USD Million)

8.6.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)

8.6.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)

Chapter 9 Company Landscape

9.1 Competitive Analysis, 2020

9.2 Intas Pharmaceuticals Ltd.

9.2.1 Company Overview

9.2.2 Financial Analysis

9.2.3 Strategic Positioning

9.2.4 Info Graphic Analysis

9.3 Access Pharmaceuticals, Inc.

9.3.1 Company Overview

9.3.2 Financial Analysis

9.3.3 Strategic Positioning

9.3.4 Info Graphic Analysis

9.4 ASKA Pharmaceutical Co.

9.4.1 Company Overview

9.4.2 Financial Analysis

9.4.3 Strategic Positioning

9.4.4 Info Graphic Analysis

9.5 Trophogen, Inc.

9.5.1 Company Overview

9.5.2 Financial Analysis

9.5.3 Strategic Positioning

9.5.4 Info Graphic Analysis

9.6 CordexPharma, Inc.

9.6.1 Company Overview

9.6.2 Financial Analysis

9.6.3 Strategic Positioning

9.6.4 Info Graphic Analysis

9.7 ZydusCadila Healthcare Ltd.

9.7.1 Company Overview

9.7.2 Financial Analysis

9.7.3 Strategic Positioning

9.7.4 Info Graphic Analysis

9.8 Bayer

9.8.1 Company Overview

9.8.2 Financial Analysis

9.8.3 Strategic Positioning

9.8.4 Info Graphic Analysis

9.9 Pfizer

9.9.1 Company Overview

9.9.2 Financial Analysis

9.9.3 Strategic Positioning

9.9.4 Info Graphic Analysis

9.10 Eli Lilly

9.10.1 Company Overview

9.10.2 Financial Analysis

9.10.3 Strategic Positioning

9.10.4 Info Graphic Analysis

9.11 Other Companies

9.11.1 Company Overview

9.11.2 Financial Analysis

9.11.3 Strategic Positioning

9.11.4 Info Graphic Analysis

The Global Point of Care or HIV Self-Test Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Point of Care or HIV Self-Test Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.